Wall Street analysts expect SeaSpine Holdings Corp (NASDAQ:SPNE) to report earnings of ($0.52) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for SeaSpine’s earnings, with the lowest EPS estimate coming in at ($0.62) and the highest estimate coming in at ($0.41). SeaSpine reported earnings of ($0.58) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 10.3%. The firm is expected to issue its next quarterly earnings report on Thursday, November 1st.

According to Zacks, analysts expect that SeaSpine will report full-year earnings of ($1.95) per share for the current year, with EPS estimates ranging from ($2.18) to ($1.81). For the next fiscal year, analysts expect that the firm will report earnings of ($1.56) per share, with EPS estimates ranging from ($1.66) to ($1.50). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow SeaSpine.

SeaSpine (NASDAQ:SPNE) last posted its earnings results on Monday, July 30th. The medical equipment provider reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). SeaSpine had a negative return on equity of 27.65% and a negative net margin of 21.75%. The firm had revenue of $36.41 million for the quarter, compared to analysts’ expectations of $34.12 million.

Several research firms have recently issued reports on SPNE. HC Wainwright reissued a “buy” rating on shares of SeaSpine in a research note on Monday, July 16th. Cantor Fitzgerald restated a “buy” rating and set a $16.00 price target on shares of SeaSpine in a research report on Monday, July 30th. Zacks Investment Research upgraded shares of SeaSpine from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Wednesday, May 9th. Finally, ValuEngine upgraded shares of SeaSpine from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $17.17.

Shares of SPNE stock traded down $0.06 during mid-day trading on Monday, hitting $14.17. 32,800 shares of the stock were exchanged, compared to its average volume of 49,195. The company has a quick ratio of 1.48, a current ratio of 3.20 and a debt-to-equity ratio of 0.04. SeaSpine has a 52-week low of $8.76 and a 52-week high of $14.55. The firm has a market cap of $204.93 million, a P/E ratio of -5.49 and a beta of 0.40.

In related news, Director Stuart Essig sold 43,496 shares of the company’s stock in a transaction dated Thursday, August 2nd. The shares were sold at an average price of $14.00, for a total transaction of $608,944.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 13.54% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in SPNE. Northern Trust Corp raised its position in shares of SeaSpine by 35.3% during the 1st quarter. Northern Trust Corp now owns 35,512 shares of the medical equipment provider’s stock worth $360,000 after purchasing an additional 9,271 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in SeaSpine by 9.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 512,823 shares of the medical equipment provider’s stock valued at $5,200,000 after acquiring an additional 43,250 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in SeaSpine by 22.3% in the 1st quarter. Russell Investments Group Ltd. now owns 406,945 shares of the medical equipment provider’s stock valued at $4,126,000 after acquiring an additional 74,160 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in SeaSpine by 29.8% in the 1st quarter. The Manufacturers Life Insurance Company now owns 382,698 shares of the medical equipment provider’s stock valued at $3,881,000 after acquiring an additional 87,891 shares during the last quarter. Finally, FNY Investment Advisers LLC acquired a new stake in SeaSpine in the 2nd quarter valued at about $892,000. Hedge funds and other institutional investors own 46.28% of the company’s stock.

SeaSpine Company Profile

SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical regions of the spine.

See Also: How Important is Technical Analysis of Stocks

Get a free copy of the Zacks research report on SeaSpine (SPNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SeaSpine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaSpine and related companies with MarketBeat.com's FREE daily email newsletter.